- Previous Rank-
- Revenue 3 Yr Annual Growth Rate33%
- Revenue 3 Yr Growth Rank45
- EPS 3 Yr Annual Growth Rate38%
- EPS 3 Yr Growth Rank51
- Total Return 3 Yr Annual Rate20%
- Total Return 3 Yr Rank61
With four FDA-approved drugs, this biotech firm based in Tarrytown, N.Y., has seen its share price surge as much as 40% this year.
Company Information
Revenue and net income for the four quarters ended on or before April 30, 2017. Total return for the period ended June 30, 2017.
| Location | Tarrytown, N.Y. |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Current Streak | - |
| Years on List | 1 |
| CEO | Leonard Schleifer |
| Website | http://www.regeneron.com |
Looking for leads, investment insights, or competitive intelligence?Purchase Now
Revenue, Net Income
| Revenue past four quarters ($M) | $4,979 |
| Net Income past four quarters ($M) | $963 |
Growth Rates and Ranks
| Revenue 3 Yr Growth Rank | 45 |
| Revenue 3 Yr Annual Growth Rate | 33% |
| EPS 3 Yr Growth Rank | 51 |
| EPS 3 Yr Annual Growth Rate | 38% |
| Total Return 3 Yr Rank | 61 |
| Total Return 3 Yr Annual Rate | 20% |
| Beat S&P 500 (9.6%) | yes |
| P/E Ratio | 45 |